American clinical stage biotechnology company in Boston, Massachusetts, founded in 2017 and listed on Nasdaq. Uses functional genomics and CRISPR based screening in human cell models to find synthetic lethal and immune evasion targets in cancers driven by loss of tumour suppressor genes, and develops small molecule medicines against them, with programmes including a PRMT5 inhibitor for MTAP deleted cancers and a USP1 inhibitor for BRCA mutant tumours.
Aucun commentaire disponible.
Laissez votre note & commentaire